Algert Global’s NovoCure NVCR Stock Holding History

Algert Global’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13M	Buy	856,322 +230,525	+37%	+$3.49M	0.15%	196
2026 Q1	$6.82M	Sell	625,797 -253,201	-29%	-$3.16M	0.1%	344
2025 Q4	$11.4M	Buy	878,998 +196,140	+29%	+$2.52M	0.18%	155
2025 Q3	$8.82M	Buy	682,858 +538,235	+372%	+$7.19M	0.15%	223
2025 Q2	$2.57M	Buy	144,623 +46,872	+48%	+$817K	0.05%	554
2025 Q1	$1.74M	Buy	97,751 +28,490	+41%	+$647K	0.04%	637
2024 Q4	$2.06M	Buy	+69,261	New	+$1.47M	0.05%	598
2024 Q3	–	Sell	-13,800	Closed	-$236K	–	1451
2024 Q2	$236K	Sell	13,800 -17,203	-55%	-$303K	0.01%	1220
2024 Q1	$485K	Buy	+31,003	New	+$456K	0.02%	767
2023 Q1	–	Sell	-5,371	Closed	-$394K	–	1254
2022 Q4	$394K	Sell	5,371 -1,336	-20%	-$101K	0.02%	872
2022 Q3	$510K	Buy	+6,707	New	+$523K	0.03%	801
2021 Q1	–	Sell	-7,841	Closed	-$1.36M	–	500
2020 Q4	$1.36M	Sell	7,841 -11,099	-59%	-$1.52M	0.39%	89
2020 Q3	$2.11M	Buy	+18,940	New	+$1.51M	0.67%	34

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Algert Global's NVCR Position: Q2 2026 in Review

Algert Global increased its NovoCure (NVCR) stake by 37% in Q2 2026, buying an estimated $3.49M and bringing the position to 856,322 shares worth $13M. The position accounts for 0.15% of the portfolio, ranked #196.

Algert Global first reported a position in NVCR in Q3 2020 and has held it in 13 quarters since. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Algert Global held 856,322 shares of NovoCure worth $13M as of Q2 2026.
Algert Global bought 230,525 NovoCure shares in Q2 2026, an estimated $3.49M.
NovoCure made up 0.15% of Algert Global's portfolio in Q2 2026, its #196 holding.
Algert Global first reported a position in NovoCure in Q3 2020 and has held it in 13 quarters since.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.